BCL2 and ovarian cancer: Xu et al. found that cisplatin resistance in ovarian cancer involved higher glucose uptake; moreover, oxidative phosphorylation was modulated by Bcl-2, and targeting Bcl-2 reversed cisplatin resistance by inhibiting glucose metabolism (Y. Xu et al., 2018).